Navigation Links
Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
Date:2/27/2008

TAMPA, Fla., Feb. 27 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that its New Drug Application (NDA) for Durezol(TM) has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review. Sirion Therapeutics is seeking approval from the FDA for its investigational compound Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a twice-daily steroid, as a treatment for postoperative ocular inflammation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

Priority review is granted by the FDA to those drugs that have the potential to provide a significant improvement compared to marketed products. This designation results in a review period of six months from the date of receipt of the NDA. The FDA has issued an action date of June 26, 2008 under the Prescription Drug User Fee Act (PDUFA).

Data from two Phase 3 clinical studies in post-operative inflammation will be presented at the American Society of Cataract and Refractive Surgery 2008 Symposium and Congress on Tuesday, April 8, 2008 at 8:32 am in room 176B at McCormick Place West in Chicago, IL.

Durezol(TM) is the trademark of Sirion Therapeutics Inc. and is currently under review by the U.S. Food and Drug Administration and has not yet been cleared as the trade name for commercial use.

About Post-Operative Inflammation

Over five million ophthalmic surgeries are performed each year in the United States. Post-operative inflammation is a common occurrence following these procedures, and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. While the inflammation tends to be self-resolving, some cases can lead to other serious conditions if left untreated. As there is no way to predict which patients might develop inflammat
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
2. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
3. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
4. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
5. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
6. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
7. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
8. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
9. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
10. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
11. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm ... Lawsuits (case #59776/2014), announces they have launched a new ... the popular hair dye, Just For Men, has caused some ... and other areas. In addition to detailing symptoms that are ... the advertisements being run by Wright & Schulte LLC will ...
(Date:7/12/2014)... Beach, FL (PRWEB) July 12, 2014 ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of ... 2014 Quinceanera dresses . The company’s new items ... fashionable without paying a large amount of money. They ... off. , The company’s online shop has become a ... occasion outfits. In addition to exquisite Quinceanera dresses, it ...
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
Breaking Medicine News(10 mins):Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2
... commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) is so potent. ... University School of Medicine, is reported online today by ... the July 2 print issue. ,It had ... cells in the intestine from absorbing cholesterol. The new ...
... Louis researchers have identified common DNA variations that ... of the eight genetic alterations the scientists identified ... vaccination. A few, however, reduced fever risk. ... same genetic variations linked to fever following smallpox ...
... to scientist at annual conference of the European Society ... abnormal can undergo chromosomal modifications. , ... Maternity Hospital, Tel Aviv Sourasky Medical Centre, Tel Aviv, ... meant that the results of preimplantation genetic screening (PGS) ...
... For many decades, medical research studies focused primarily on ... applied to women. But we now know that the ... women are more than skin deep. Beginning in 1990, ... based advocacy organization, conveyed to a national audience the ...
... and their friends filled the area in and around the ... 14th annual Komen Puget Sound Race for the Cure . ... cancer, while many others were running to honor family members ... in the pink T-shirts and sporting the medallions awarded by ...
... much as $2.7 billion a year, according to the Access ... of Crohn's disease and ulcerative colitis. Crohn's disease is a ... ulcerations (breaks in the lining) of the small and large ... mouth to the anus. It is named after the physician ...
Cached Medicine News:Health News:Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 3Health News:Preimplanted Genetic Screening Should Be Interpreted With Caution 2Health News:Rare Womens Lung Disease May Yield Insights Into Common Diseases 2Health News:Annual Cancer Run Draws Huge Response in US 2Health News:Inflamed Intestines Cost Australians Heavily 2
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: